Şunu aradınız:: hpv vaccine (İngilizce - Maltaca)

hpv type
tip ta’ hpv

hpv-18
hpv- 18

hpv 16/18-
8487

10 non-vaccine hpv types║
10 tipi ta’ hpv mhux vaċċin║

hpv hpv hpv hpv hpv
26. 2, 74. 1 †

gardasil was efficacious against hpv disease caused by each of the four vaccine hpv type.
gardasil kien effikaċji kontra l - mard tal- hpv ikkawżat minn kull wieħed mill- erba ’ tipi ta ’ vaċċin hpv.

gardasil was efficacious against hpv disease caused by each of the four vaccine hpv types.
gardasil kien effikaċji kontra l- mard tal-hpv ikkawżat minn kull wieħed mill-erba’ tipi ta’ vaċċin hpv.

efficacy in men naïve to the relevant vaccine hpv types
effikaċja fl-irġiel li qatt ma kellhom it-tipi ta’ hpv tat-tilqima

overall impact of the vaccine on cervical hpv disease burden
impatt globali tal-vaċċin fuq il-piż ta’mard tal-għonq tal-utru b’hpv

(hpv 31/ 33/ 45/ 52/ 58) § 10 non-vaccine hpv types ║
(hpv 31/ 33/ 45/ 52/ 58) § 10 tipi ta ’ hpv mhux vaċċin║

if you or your child already received an hpv vaccine, ask your doctor if gardasil 9 is right for you.
jekk inti jew ibnek/bintek diġà ħadtu vaċċin ta’ hpv, staqsi lit-tabib tiegħek jekk gardasil 9 jgħoddx għalik.

although fainting episodes are uncommon, patients should be observed for 15 minutes after they receive hpv vaccine.
għalkemm episodji ta’ ħassħażin m’humiex komuni, il-pazjenti għandhom jiġu osservati għal 15-il minuta wara li huma jirċievu tilqima tal-hpv.

antibody responses to menveo and the diphtheria, tetanus or hpv vaccine components were not negatively affected by co-administration.
risponsi ta’ antikorpi għal menveo u l-komponenti tal-vaċċin kontra d-difterija, it-tetnu jew l-hpv ma kinux affettwati b’mod negattiv minn għoti flimkien.

table 7: vaccine efficacy against 6m pi with hpv 16/18 in atp and tvc
tabella 7: effikaċja tal-vaċċin kontra 6m pi b’hpv 16/18 f’atp u tvc

when gardasil is given as your first dose, the completion of the vaccination course should be done with gardasil, and not with another hpv vaccine.
meta gardasil jingħata bħala l-ewwel doża tiegħek, il-kors ta’ tilqim għandu jitkompla b’gardasil, u mhux b’vaċċin għall-hpv ieħor.

premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine hpv types
leżjonijiet qabel isiru malinni u kanċers li jaffettwaw l-għonq tal-utru, il-vulva, il-vaġina u l- anus ikkawżati mit-tipi ta’ hpv tal-vaċċin

one study compared the level of protective antibodies developed in adult women after cervarix use and compared it with those of another hpv vaccine already authorised for anal lesions and cancer.
studju wieħed qabbel il-livell ta' antikorpi protettivi żviluppati f'nisa adulti wara l-użu ta' cervarix ma' dawk ta' vaċċin ieħor tal-hpv diġà awtorizzat għal leżjonijiet u kanċer anali.

type-specific immunoassays with type-specific standards were used to assess immunogenicity to each vaccine hpv type.
analiżi ta’ immunità speċifika għat-tip bi standards speċifiċi għat-tip intużaw biex jistmaw l- immunoġeniċità għal kull tip ta’ hpv tal-vaċċin.

efficacy against disease endpoints caused by pre-specified combinations of non-vaccine hpv types was measured.
l- effikaċja kontra punti ta ’ tmiem tal- marda ikkawżata 9 minn kombinazzjonijiet pre- speċifikati ta ’ tipi hpv tal- vaċċin ġiet imkejla.

no minimum antibody level associated with protection has been identified for hpv vaccines.
l-ebda livell ta’ anti-korpi minimu marbut mal-protezzjoni ma kien identifikat għall-vaċċini hpv.